Trade Viking Therapeutics, Inc. - VKTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.25 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.025096% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002874% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 64.07 |
| Open | 65.02 |
| 1-Year Change | 501.48% |
| Day's Range | 64.39 - 65.02 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 3, 2024 | 64.07 | -0.37 | -0.57% | 64.44 | 66.29 | 63.37 |
| Oct 2, 2024 | 64.64 | 2.89 | 4.68% | 61.75 | 64.76 | 61.15 |
| Oct 1, 2024 | 61.93 | -1.04 | -1.65% | 62.97 | 63.36 | 60.51 |
| Sep 30, 2024 | 63.26 | 1.63 | 2.64% | 61.63 | 64.47 | 61.42 |
| Sep 27, 2024 | 61.58 | -0.64 | -1.03% | 62.22 | 63.14 | 61.24 |
| Sep 26, 2024 | 62.28 | -0.61 | -0.97% | 62.89 | 63.82 | 61.27 |
| Sep 25, 2024 | 63.04 | 0.44 | 0.70% | 62.60 | 65.51 | 62.10 |
| Sep 24, 2024 | 61.87 | -2.60 | -4.03% | 64.47 | 64.47 | 61.53 |
| Sep 23, 2024 | 64.96 | -5.08 | -7.25% | 70.04 | 70.04 | 64.56 |
| Sep 20, 2024 | 70.42 | 1.17 | 1.69% | 69.25 | 72.28 | 68.46 |
| Sep 19, 2024 | 68.12 | 1.84 | 2.78% | 66.28 | 68.14 | 64.98 |
| Sep 18, 2024 | 64.40 | 1.41 | 2.24% | 62.99 | 65.95 | 62.55 |
| Sep 17, 2024 | 62.90 | -3.18 | -4.81% | 66.08 | 66.84 | 62.18 |
| Sep 16, 2024 | 67.03 | 0.93 | 1.41% | 66.10 | 68.72 | 64.47 |
| Sep 13, 2024 | 66.66 | 3.70 | 5.88% | 62.96 | 67.80 | 62.60 |
| Sep 12, 2024 | 62.71 | 0.36 | 0.58% | 62.35 | 64.55 | 62.32 |
| Sep 11, 2024 | 60.77 | 4.45 | 7.90% | 56.32 | 61.02 | 55.87 |
| Sep 10, 2024 | 54.59 | -0.08 | -0.15% | 54.67 | 55.14 | 52.61 |
| Sep 9, 2024 | 54.70 | -1.25 | -2.23% | 55.95 | 55.95 | 53.88 |
| Sep 6, 2024 | 54.06 | -1.39 | -2.51% | 55.45 | 55.49 | 51.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Viking Therapeutics, Inc. Company profile
About Viking Therapeutics Inc
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Viking Therapeutics Inc revenues was not reported. Net loss increased 39% to $55M. Higher net loss reflects Other Research and Development. increase of 42% to $43.4M (expense), Interest Income - Net decrease of 78% to $703K (income), Stock-based Compensation in R&D increase of 19% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.54 to -$0.71.
| Industry: | Bio Therapeutic Drugs |
9920 Pacific Heights Blvd, Suite 350
SAN DIEGO
CALIFORNIA 92121
US
News
September US Non-Farm Payrolls Preview
Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.
07:59, 2 October 2024
Market of the Month - Gold, an overview
In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.
06:00, 30 September 2024
RBA Preview: Rates to remain unchanged with inflation-fighting still the focus
RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.
12:27, 20 September 2024
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com